文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

纤溶酶原激活物抑制物1调控心肌细胞TGF-β与心脏纤维化

Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.
PubMed 文献 · Circulation · 2017-06-06

该研究通过SERPINE-1纯合突变个体的心脏磁共振及小鼠血管紧张素II心脏损伤模型,发现PAI-1缺陷与心脏选择性纤维化相关。机制上,PAI-1抑制心肌细胞TGF-β产生,其缺失增强TGF-β信号转录,揭示PAI-1是心脏纤维化的关键抑制因子。

要点

  • PAI-1完全缺陷的2名健康人出现心脏纤维化。
  • PAI-1-/-小鼠血管紧张素II诱导心肌肥厚和纤维化加重。
  • PAI-1通过抑制心肌细胞TGF-β合成调控心脏纤维化。

核心结论

  • PAI-1是哺乳动物心脏纤维化的重要抑制因子,通过心肌细胞特异性机制调控TGF-β产生,解释其缺陷促发心脏选择性纤维化的矛盾现象。

研究设计与样本

  • 评估2例SERPINE-1纯合移码突变致PAI-1完全缺陷者的心脏纤维化(晚期钆增强心脏磁共振)。
  • 使用血管紧张素II皮下输注的野生型和PAI-1-/-小鼠心脏损伤模型,评估血压、心脏功能(超声心动图)、纤维化(Masson三色染色)和凋亡(TUNEL染色)。
  • 进行心室RNA测序转录组分析,并评估离体小鼠原代心室肌细胞的纤维化信号。

主要发现

  • 2例PAI-1完全缺陷的健康人检出心脏纤维化。
  • 血管紧张素II处理的年轻PAI-1-/-小鼠出现广泛肥厚和纤维化心肌病,伴心脏凋亡增加及反应性和替代性纤维化。
  • PAI-1-/-小鼠血管紧张素II诱导的高血压减弱,但心脏肥厚加速。
  • 心室肌细胞是心脏TGF-β的重要来源,PAI-1在体外和体内心脏损伤中调控心肌细胞TGF-β合成。
  • 血管紧张素II处理后PAI-1-/-小鼠心室转录组显示多个TGF-β信号元件和转录靶点显著增强,包括细胞外基质成分、重塑介质、基质细胞蛋白和心脏整合素基因。

临床怎么用

  • PAI-1可作为心脏纤维化的潜在生物标志物或治疗靶点,但需进一步临床验证。
  • 在PAI-1缺陷或低水平患者中,应警惕心脏纤维化风险,即使血压不高。
  • 调控PAI-1-TGF-β轴可能成为抗心肌纤维化策略,尤其针对心肌细胞特异性通路。

局限性

  • 人类证据仅基于2例PAI-1完全缺陷个体,样本量小。
  • 动物模型使用血管紧张素II诱导,不能完全代表所有心脏损伤类型。
  • 研究未报告纤维化定量、统计学比较的具体数值(如P值、置信区间)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibrosis is the pathological consequence of stress-induced tissue remodeling and matrix accumulation. Increased levels of plasminogen activator inhibitor type I (PAI-1) have been shown to promote fibrosis in multiple organ systems. Paradoxically, homozygous genetic deficiency of PAI-1 is associated with spontaneous age-dependent, cardiac-selective fibrosis in mice. We have identified a novel PAI-1-dependent mechanism that regulates cardiomyocyte-derived fibrogenic signals and cardiac transcriptional pathways during injury. METHODS: Cardiac fibrosis in subjects with homozygous mutation in SERPINE-1 was evaluated with late gadolinium-enhanced cardiac magnetic resonance imaging. A murine cardiac injury model was performed by subcutaneous infusion of either saline or Angiotensin II by osmotic minipumps. We evaluated blood pressure, cardiac function (by echocardiography), fibrosis (with Masson Trichrome staining), and apoptosis (with TUNEL staining), and we performed transcriptome analysis (with RNA sequencing). We further evaluated fibrotic signaling in isolated murine primary ventricular myocytes. RESULTS: Cardiac fibrosis was detected in 2 otherwise healthy humans with complete PAI-1 deficiency because of a homozygous frameshift mutation in SERPINE-1. In addition to its suppressive role during spontaneous cardiac fibrosis in multiple species, we hypothesized that PAI-1 also regulates fibrosis during cardiac injury. Treatment of young PAI-1-/- mice with Angiotensin II induced extensive hypertrophy and fibrotic cardiomyopathy, with increased cardiac apoptosis and both reactive and replacement fibrosis. Although Angiotensin II-induced hypertension was blunted in PAI-1-/- mice, cardiac hypertrophy was accelerated. Furthermore, ventricular myocytes were found to be an important source of cardiac transforming growth factor-β (TGF-β) and PAI-1 regulated TGF-β synthesis by cardiomyocytes in vitro as well as in vivo during cardiac injury. Transcriptome analysis of ventricular RNA after Angiotensin II treatment confirmed that PAI-1 deficiency significantly enhanced multiple TGF-β signaling elements and transcriptional targets, including genes for extracellular matrix components, mediators of extracellular matrix remodeling, matricellular proteins, and cardiac integrins compared with wild-type mice. CONCLUSIONS: PAI-1 is an essential repressor of cardiac fibrosis in mammals. We define a novel cardiomyocyte-specific regulatory mechanism for TGF-β production by PAI-1, which explains the paradoxical effect of PAI-1 deficiency in promoting cardiac-selective fibrosis. Thus, PAI-1 is a molecular switch that controls the cardiac TGF-β axis and its early transcriptional effects that lead to myocardial fibrosis.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Flevaris P, Khan SS, Eren M, et al. Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis. Circulation. 2017. PMID: 28588076. doi:10.1161/CIRCULATIONAHA.117.028145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。